A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above

PHASE3CompletedINTERVENTIONAL

Enrollment

1,544

Participants

Timeline

Start Date

October 28, 2022

Primary Completion Date

March 13, 2023

Study Completion Date

February 12, 2024

Conditions

Respiratory Syncytial Virus Infections

Interventions

BIOLOGICAL

RSVPreF3 OA investigational vaccine

One dose administered intramuscularly at Day 1.

DRUG

Placebo

One dose administered intramuscularly at Day 1.